Earnings Data
Report Date
Aug 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-1.41Last Year’s EPS
-5.49Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Quoin Pharmaceuticals, with significant progress in clinical trials, strong commercial partnerships, and a solid financial position. However, challenges remain in managing cash burn and executing M&A strategies.Company Guidance
Transformational Year for Quoin
2023 was a transformational year for Quoin, marked by the release of the first-ever clinical data from a trial in Netherton syndrome subjects under an open IND with the FDA. The initial data was positive across several clinical endpoints with no safety signals.
Successful Protocol Amendments
The FDA cleared several protocol amendments, including increasing study sizes, changing dosing frequency, and lowering eligibility age to 14 years. These changes aim to generate more robust data sets and potentially expedite recruitment.
Strong Commercial Partnerships
Quoin has entered into 9 commercial partnerships covering 61 countries, which will facilitate a global launch of QRX003 once approved. This global network is unprecedented for a company of Quoin's size.
Positive Financial Position
Quoin completed a $6.5 million public offering, and entered an $8 million equity line of credit, extending the cash runway into the second half of 2026. The net loss decreased from $9.4 million in 2022 to $8.7 million in 2023.
DE:2EB0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:2EB0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | €5.00 | €5.10 | +2.00% |
Mar 26, 2026 | €6.54 | €7.22 | +10.40% |
Nov 06, 2025 | €8.42 | €8.20 | -2.61% |
Aug 07, 2025 | €6.00 | €5.76 | -4.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Quoin Pharmaceuticals Ltd (DE:2EB0) report earnings?
Quoin Pharmaceuticals Ltd (DE:2EB0) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
What is Quoin Pharmaceuticals Ltd (DE:2EB0) earnings time?
Quoin Pharmaceuticals Ltd (DE:2EB0) earnings time is at Aug 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Quoin Pharmaceuticals Ltd stock?
The P/E ratio of Quoin Pharmaceuticals is N/A.
What is DE:2EB0 EPS forecast?
DE:2EB0 EPS forecast for the fiscal quarter 2026 (Q2) is -1.41.